Peptides emerge as a frontier drug modality
Peptides have moved from a niche chemistry into one of the most active frontiers in drug development, spanning metabolic disease, oncology, anti-infectives and longevity. The category covers FDA-approved GLP-1 receptor agonists for obesity and diabetes alongside a wider research pipeline of next-generation and multi-target peptides, growth-hormone secretagogues, tissue-repair peptides such as BPC-157, and copper peptides such as GHK-copper.
Two dynamics have accelerated commercial interest. First, the runaway demand for GLP-1 medicines created supply shortages that pulled compounding pharmacies and telehealth providers into the market, raising regulatory and sourcing questions around compounded and gray-market supply. Second, advances in computational design and machine learning have made it possible to discover and engineer novel peptides far faster than traditional screening allowed, lowering the barrier to building new therapeutics on this modality.
The result is a fast-growing stack of companies: drug developers advancing next-generation GLP-1 and metabolic peptides, platform businesses applying AI to peptide and protein design, oral-delivery specialists working to overcome peptides' poor bioavailability, and the contract manufacturers scaling synthesis to meet demand.
The science, clinical uses and safety considerations of peptides are discussed at length in the podcast episode Peptides: The Science, Uses & Safety (with Dr Abud Bakri).
Read more: Dealroom — Peptides: the next drug modality stack
